Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Colorcon
Moodys
Harvard Business School
Johnson and Johnson

Last Updated: June 28, 2022

Ixabepilone - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for ixabepilone and what is the scope of freedom to operate?

Ixabepilone is the generic ingredient in one branded drug marketed by R-pharm Us Llc and is included in one NDA. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ixabepilone has one hundred and fifty-five patent family members in thirty-five countries.

There is one drug master file entry for ixabepilone. One supplier is listed for this compound.

Summary for ixabepilone
International Patents:155
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 50
Clinical Trials: 114
Patent Applications: 7,102
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in ixabepilone?ixabepilone excipients list
DailyMed Link:ixabepilone at DailyMed
Recent Clinical Trials for ixabepilone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Allarity TherapeuticsPhase 2
R-Pharm US, Inc.Phase 2
Yale UniversityPhase 2

See all ixabepilone clinical trials

Paragraph IV (Patent) Challenges for IXABEPILONE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
IXEMPRA KIT Injection ixabepilone 15 mg/vial and 45 mg/vial, single- use vials 022065 1 2012-04-16

US Patents and Regulatory Information for ixabepilone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-002 Oct 16, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-001 Oct 16, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-001 Oct 16, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-001 Oct 16, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-002 Oct 16, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-002 Oct 16, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-001 Oct 16, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ixabepilone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-002 Oct 16, 2007 See Plans and Pricing See Plans and Pricing
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-002 Oct 16, 2007 See Plans and Pricing See Plans and Pricing
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-001 Oct 16, 2007 See Plans and Pricing See Plans and Pricing
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-001 Oct 16, 2007 See Plans and Pricing See Plans and Pricing
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-002 Oct 16, 2007 See Plans and Pricing See Plans and Pricing
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-001 Oct 16, 2007 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ixabepilone

Country Patent Number Title Estimated Expiration
Norway 20130070 See Plans and Pricing
Hungary 0303175 See Plans and Pricing
Russian Federation 2003130377 See Plans and Pricing
Estonia 05301 Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks See Plans and Pricing
Russian Federation 2003126174 See Plans and Pricing
Slovenia 1353668 See Plans and Pricing
Mexico PA03006485 FORMULACION PARENTERAL QUE CONTIENE ANALOGOS DE EPOTILONA. (PARENTERAL FORMULATION CONTAINING EPOTHILONE ANALOGS.) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Boehringer Ingelheim
Express Scripts
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.